These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 33825507)
41. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiators protect G551D but not ΔF508 CFTR from thermal instability. Liu X; Dawson DC Biochemistry; 2014 Sep; 53(35):5613-8. PubMed ID: 25148434 [TBL] [Abstract][Full Text] [Related]
42. ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and Promotion of Nitric Oxide Signaling to the Cystic Fibrosis Transmembrane Conductance Regulator Channel. Wu YS; Jiang J; Ahmadi S; Lew A; Laselva O; Xia S; Bartlett C; Ip W; Wellhauser L; Ouyang H; Gonska T; Moraes TJ; Bear CE Mol Pharmacol; 2019 Oct; 96(4):515-525. PubMed ID: 31427400 [TBL] [Abstract][Full Text] [Related]
43. Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation. Sermet-Gaudelus I Eur Respir Rev; 2013 Mar; 22(127):66-71. PubMed ID: 23457167 [TBL] [Abstract][Full Text] [Related]
44. Ivacaftor as salvage therapy in a patient with cystic fibrosis genotype F508del/R117H/IVS8-5T. Carter S; Kelly S; Caples E; Grogan B; Doyle J; Gallagher CG; McKone EF J Cyst Fibros; 2015 Jul; 14(4):e4-5. PubMed ID: 25698453 [TBL] [Abstract][Full Text] [Related]
45. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. Van Goor F; Yu H; Burton B; Hoffman BJ J Cyst Fibros; 2014 Jan; 13(1):29-36. PubMed ID: 23891399 [TBL] [Abstract][Full Text] [Related]
47. Effects of Lumacaftor-Ivacaftor on Lung Clearance Index, Magnetic Resonance Imaging, and Airway Microbiome in Phe508del Homozygous Patients with Cystic Fibrosis. Graeber SY; Boutin S; Wielpütz MO; Joachim C; Frey DL; Wege S; Sommerburg O; Kauczor HU; Stahl M; Dalpke AH; Mall MA Ann Am Thorac Soc; 2021 Jun; 18(6):971-980. PubMed ID: 33600745 [No Abstract] [Full Text] [Related]
48. In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies. McGarry ME; Illek B; Ly NP; Zlock L; Olshansky S; Moreno C; Finkbeiner WE; Nielson DW Pediatr Pulmonol; 2017 Apr; 52(4):472-479. PubMed ID: 28068001 [TBL] [Abstract][Full Text] [Related]
49. Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against Pseudomonas aeruginosa?-Results of an in vitro study. Millar BC; Rendall JC; Downey DG; Moore JE J Clin Pharm Ther; 2018 Dec; 43(6):836-843. PubMed ID: 29959786 [TBL] [Abstract][Full Text] [Related]
50. Cystic fibrosis drug ivacaftor stimulates CFTR channels at picomolar concentrations. Csanády L; Töröcsik B Elife; 2019 Jun; 8():. PubMed ID: 31205003 [TBL] [Abstract][Full Text] [Related]
51. Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis. Derichs N Eur Respir Rev; 2013 Mar; 22(127):58-65. PubMed ID: 23457166 [TBL] [Abstract][Full Text] [Related]
52. GLPG1837, a CFTR potentiator, in p.Gly551Asp (G551D)-CF patients: An open-label, single-arm, phase 2a study (SAPHIRA1). Davies JC; Van de Steen O; van Koningsbruggen-Rietschel S; Drevinek P; Derichs N; McKone EF; Kanters D; Allamassey L; Namour F; de Kock H; Conrath K J Cyst Fibros; 2019 Sep; 18(5):693-699. PubMed ID: 31147302 [TBL] [Abstract][Full Text] [Related]
58. Two rare variants that affect the same amino acid in CFTR have distinct responses to ivacaftor. Li H; Rodrat M; Al-Salmani MK; Veselu DF; Han ST; Raraigh KS; Cutting GR; Sheppard DN J Physiol; 2024 Jan; 602(2):333-354. PubMed ID: 38186087 [TBL] [Abstract][Full Text] [Related]
59. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trial. Quittner A; Suthoff E; Rendas-Baum R; Bayliss MS; Sermet-Gaudelus I; Castiglione B; Vera-Llonch M Health Qual Life Outcomes; 2015 Jul; 13():93. PubMed ID: 26135562 [TBL] [Abstract][Full Text] [Related]
60. Two Small Molecules Restore Stability to a Subpopulation of the Cystic Fibrosis Transmembrane Conductance Regulator with the Predominant Disease-causing Mutation. Meng X; Wang Y; Wang X; Wrennall JA; Rimington TL; Li H; Cai Z; Ford RC; Sheppard DN J Biol Chem; 2017 Mar; 292(9):3706-3719. PubMed ID: 28087700 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]